346 related articles for article (PubMed ID: 29132650)
1. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease.
Nishimura M; Hsu JC
Am J Cardiol; 2018 Jan; 121(1):131-140. PubMed ID: 29132650
[TBL] [Abstract][Full Text] [Related]
2. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
[TBL] [Abstract][Full Text] [Related]
3. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763
[TBL] [Abstract][Full Text] [Related]
4. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
Kumar S; Danik SB; Altman RK; Barrett CD; Lip GY; Chatterjee S; Roubin GS; Natale A; Danik JS
Cardiol Rev; 2016; 24(5):218-23. PubMed ID: 26274538
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulants in patients with atrial fibrillation and end-stage renal disease.
Brimble KS; Ingram AJ; Eikelboom JW; Hart RG
Postgrad Med; 2012 Nov; 124(6):17-25. PubMed ID: 23322135
[TBL] [Abstract][Full Text] [Related]
6. Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
Mlodawska E; Lopatowska P; Malyszko J; Banach M; Sobkowicz B; Covic A; Tomaszuk-Kazberuk A
Int Urol Nephrol; 2018 Sep; 50(9):1633-1642. PubMed ID: 29785661
[TBL] [Abstract][Full Text] [Related]
7. Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease.
Potpara TS; Jokic V; Dagres N; Larsen TB; Lane DA; Hindricks G; Lip GY
Curr Med Chem; 2016; 23(19):2055-69. PubMed ID: 26861000
[TBL] [Abstract][Full Text] [Related]
8. [NOACs and Chronic kidney disease].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Mar; 34(Suppl 69):188-204. PubMed ID: 28682039
[TBL] [Abstract][Full Text] [Related]
9. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.
Potpara TS; Ferro CJ; Lip GYH
Nat Rev Nephrol; 2018 May; 14(5):337-351. PubMed ID: 29578207
[TBL] [Abstract][Full Text] [Related]
10. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
12. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.
Verheugt FW; Granger CB
Lancet; 2015 Jul; 386(9990):303-10. PubMed ID: 25777666
[TBL] [Abstract][Full Text] [Related]
13. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis.
Tan J; Liu S; Segal JB; Alexander GC; McAdams-DeMarco M
BMC Nephrol; 2016 Oct; 17(1):157. PubMed ID: 27769175
[TBL] [Abstract][Full Text] [Related]
14. Non-Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non-Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis.
Sitticharoenchai P; Takkavatakarn K; Boonyaratavej S; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
J Am Heart Assoc; 2021 Apr; 10(7):e019609. PubMed ID: 33728927
[TBL] [Abstract][Full Text] [Related]
15. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular and renal protective effects of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation.
Choi SH; Kim M; Kim H; Kim DH; Baek YS
PLoS One; 2022; 17(10):e0275103. PubMed ID: 36227869
[TBL] [Abstract][Full Text] [Related]
17. Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines.
Młodawska E; Tomaszuk-Kazberuk A; Łopatowska P; Musiał WJ; Małyszko J
Pol Arch Med Wewn; 2016 May; 126(5):353-62. PubMed ID: 27243343
[TBL] [Abstract][Full Text] [Related]
18. Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation.
Steinberg BA; Washam JB
Trends Cardiovasc Med; 2017 Nov; 27(8):567-572. PubMed ID: 28750830
[TBL] [Abstract][Full Text] [Related]
19. [Atrial fibrillation in severe and end stage renal disease: from oral anticoagulation therapy to percutaneous left atrial appendage occlusion].
Merella P; Casu G; Mazzone P; Lorenzoni G; D'Angelo G; Genovesi S
G Ital Nefrol; 2019 Feb; 36(1):. PubMed ID: 30758149
[TBL] [Abstract][Full Text] [Related]
20. Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction.
Mahmood M; Lip GYH
Rev Esp Cardiol (Engl Ed); 2018 Oct; 71(10):847-855. PubMed ID: 29958809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
